Log In
BCIQ
Print this Print this
 

GRT6006

  Manage Alerts
Collapse Summary General Information
Company Gruenenthal Group
DescriptionOral small molecule analgesic
Molecular Target Opioid related nociceptin receptor 1 (OPRL1) (NOPR) ; Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat neuropathic pain
Regulatory Designation
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/13/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today